Inovio Pharmaceuticals (INO) AI Stock Analysis

• Market Cap: $73.89M
• Dividend Yield: N/A
• Average Volume (3M): 2.41M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.71
• Revenue Growth: -60.52%
• EPS Growth: 42.41%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.51
• Shares Outstanding: 50,960,150
• 10 Day Avg. Volume: 2,444,972
• 30 Day Avg. Volume: 2,406,091
• PEG Ratio: -0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: -387.00
• Enterprise Value/Revenue: -23.23K
• Enterprise Value/Gross Profit: 20.62K
• Enterprise Value/Ebitda: 1.12
• 1Y Price Target: $7.60
• Price Target Upside: 387.18% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 43 Neutral
• Price Target: $1.50 ▼(-3.85%Downside)

Inovio Pharmaceuticals' stock score reflects significant financial challenges and bearish technical indicators, counterbalanced slightly by potential clinical progress and strategic milestones as discussed in the earnings call. The primary concerns are the company's ongoing financial losses, negative cash flows, and lack of revenue growth, which weigh heavily on the overall score.

Positive Factors

Clinical Efficacy

INO-3107 was well tolerated and achieved robust clinical efficacy with 81% of patients requiring fewer surgeries and 28% no surgeries following treatment.

Patient and Payer Uptake

Top-line results point to sustained and deepening responses, which are encouraging for eventual patient and payer uptake.

Regulatory Progress

INO-3107 has been granted Breakthrough Therapy designation for the treatment of recurrent respiratory papillomatosis (RRP) by the FDA.

Negative Factors

Clinical Trial Requirements

The company needs to update IND and initiate a confirmatory trial before the BLA submission.

Regulatory Approval Risks

INO-3107 may not gain regulatory approval in RRP or meet sales forecasts.

Technological Risks

DNA-encoded medicines are novel and may fail in the clinic or in practice.

Inovio Pharmaceuticals Business Overview & Revenue Model

Company Description

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing DNA medicines to treat and prevent infectious diseases, cancer, and other challenging conditions. The company's core technology platform involves the design and delivery of DNA plasmids to produce a robust immune response against targeted diseases. Headquartered in Plymouth Meeting, Pennsylvania, Inovio is actively engaged in clinical trials and research collaborations to advance its pipeline of innovative therapies.

How the Company Makes Money

Inovio Pharmaceuticals makes money primarily through the development and commercialization of its DNA-based immunotherapy products. The company generates revenue through licensing agreements, collaborations, and research grants with larger pharmaceutical and biotechnology companies, as well as government and non-governmental organizations. Inovio's partnerships often involve upfront payments, milestone payments, and potential royalties on sales of products developed using its technology. Additionally, the company may receive funding from grants and contracts for specific research and development projects. As Inovio advances its product candidates through clinical trials, successful commercialization of these therapies could lead to significant revenue generation through direct sales or additional partnerships.

Inovio Pharmaceuticals Financial Statement Overview

Summary

Inovio Pharmaceuticals is experiencing significant financial struggles, marked by continuous losses and negative cash flows. Although the balance sheet shows a strong equity position, the lack of profitability and reliance on financing are concerning.

Income Statement

Inovio Pharmaceuticals exhibits a challenging financial position with consistent negative net income and EBIT over the years. The company shows no revenue growth and gross profit margins are negative, indicating cost management issues or insufficient revenue to cover costs. The absence of gross profit and negative EBIT margins reflect the company's ongoing struggle with profitability.

Balance Sheet

The balance sheet reveals a relatively stable equity position with stockholders' equity being significantly higher than total debt, resulting in a low debt-to-equity ratio. However, the company has been heavily reliant on equity financing, as indicated by the substantial stockholders' equity compared to total assets. Despite the strong equity base, the company has not converted this into profitability or growth.

Cash Flow

Cash flow analysis indicates a negative operating and free cash flow, showing difficulties in generating cash from operations. The company has relied on financing activities to sustain operations, which may not be sustainable long-term. The absence of positive free cash flow growth further highlights challenges in cash generation.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	217.76K	832.01K	10.26M	1.77M	7.41M
Gross Profit	-2.91M	-2.67M	4.77M	-2.96M	-86.83M
EBITDA	-103.95M	-130.39M	-270.90M	-296.56M	-149.56M
Net Income	-107.25M	-135.12M	-287.66M	-305.38M	-215.09M
Balance Sheet
Total Assets	113.20M	170.95M	348.53M	495.94M	539.77M
Cash, Cash Equivalents and Short-Term Investments	94.11M	145.29M	253.00M	401.31M	411.64M
Total Debt	11.87B	30.21M	32.07M	33.02M	39.05M
Total Liabilities	44.69M	53.60M	126.17M	96.27M	78.63M
Stockholders Equity	68.50B	117.35M	222.36M	399.67M	461.14M
Cash Flow
Free Cash Flow	-104.56M	-124.69M	-217.18M	-216.94M	-179.50M
Operating Cash Flow	-104.08M	-124.37M	-216.22M	-215.71M	-177.98M
Investing Cash Flow	104.07M	87.36M	109.59M	-175.34M	-58.80M
Financing Cash Flow	51.48M	5.00M	81.84M	211.50M	465.28M

Inovio Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INO, the sentiment is Negative. The current price of 1.56 is below the 20-day moving average (MA) of 1.61, below the 50-day MA of 1.87, and below the 200-day MA of 2.67, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 46.20 is Neutral, neither overbought nor oversold. The STOCH value of 78.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INO.

Inovio Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VTGN	57 Neutral	$74.06M	―	-46.28%	―	-33.00%	54.91%
Sector *	52 Neutral	$7.61B	0.04	-62.94%	2.44%	16.14%	0.33%
INO	43 Neutral	$73.89M	―	-132.44%	―	-60.52%	42.41%
SAVA	43 Neutral	$130.43M	―	-70.59%	―	―	81.00%
IFRX	42 Neutral	$57.65M	―	-62.38%	―	178.84%	-40.60%
ABOS	36 Underperform	$101.16M	―	-55.68%	―	―	-57.45%
JSPR	35 Underperform	$47.32M	―	-101.34%	―	―	21.40%

Inovio Pharmaceuticals Corporate Events

Inovio Pharmaceuticals Announces Public Offering Agreement

On July 2, 2025, INOVIO Pharmaceuticals entered into an underwriting agreement with Piper Sandler & Co. for a public offering of 14,285,715 shares of common stock and accompanying Series A and B warrants. The company expects net proceeds of approximately $22.5 million from the offering, which is anticipated to close around July 7, 2025, subject to customary conditions. This move is expected to bolster INOVIO’s financial position, potentially impacting its market presence and stakeholder interests.

The most recent analyst rating on (INO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Inovio Pharmaceuticals stock, see the INO Stock Forecast page.

Inovio Pharmaceuticals Holds Annual Stockholders Meeting

On May 20, 2025, Inovio Pharmaceuticals held its Annual Meeting of Stockholders where four proposals were considered. The proposals included the election of eight directors, the ratification of Ernst & Young LLP as the independent auditor, approval of executive compensation, and amendment of the 2023 Omnibus Incentive Plan. Each proposal received varying levels of support from the stockholders, reflecting the company’s ongoing governance and strategic planning efforts.

The most recent analyst rating on (INO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Inovio Pharmaceuticals stock, see the INO Stock Forecast page.